+
Lupin and Zentiva Sign Pact to Commercialise Certolizumab
ECONOMY & POLICY

Lupin and Zentiva Sign Pact to Commercialise Certolizumab

Global Pharma major Lupin (Lupin) and Zentiva Group (Zentiva), a pan-European pharmaceutical company, have entered into a license and supply agreement for commercialisation of Lupin’s biosimilar Certolizumab Pegol, across multiple markets globally.

This strategic alliance aims to accelerate the availability of high-quality, cost-effective biosimilar Certolizumab Pegol to patients worldwide.

Lupin will be responsible for the development, manufacturing and supply of the product within the agreed territories. Zentiva will oversee commercialization activities outside USA and Canada, predominantly in Europe and CIS markets, where it will leverage its extensive European commercial infrastructure and regulatory expertise. Lupin will undertake commercialization in the remaining regions, including USA and Canada.

Both parties will invest in the development of the new biosimilar. Lupin will receive an initial payment of $10 million upon execution of the agreement and total development and regulatory milestone payments up to $50 million. The profits from the defined markets will be shared between the two companies.

Certolizumab Pegol is a recombinant, humanized antibody Fab' fragment, with specificity for human tumor necrosis factor alpha (TNFα), conjugated to an approximately 40kDa polyethylene glycol. It is indicated for the treatment of patients with rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, psoriatic arthritis, non-radiographic axial spondyloarthritis, moderate-to-severe plaque psoriasis and Crohn’s disease.

“Our global development and commercialization partnership with Zentiva, with its pan- European focus, enables Lupin to commercialize this unique biosimilar in its core markets and through Zentiva in Europe,” said Fabrice Egros, President of Corporate Development, Lupin. “This partnership underscores our dedication to improving the quality of life for individuals living with chronic conditions and ensuring accessibility and affordability of transformative therapies worldwide."

Global Pharma major Lupin (Lupin) and Zentiva Group (Zentiva), a pan-European pharmaceutical company, have entered into a license and supply agreement for commercialisation of Lupin’s biosimilar Certolizumab Pegol, across multiple markets globally.This strategic alliance aims to accelerate the availability of high-quality, cost-effective biosimilar Certolizumab Pegol to patients worldwide.Lupin will be responsible for the development, manufacturing and supply of the product within the agreed territories. Zentiva will oversee commercialization activities outside USA and Canada, predominantly in Europe and CIS markets, where it will leverage its extensive European commercial infrastructure and regulatory expertise. Lupin will undertake commercialization in the remaining regions, including USA and Canada.Both parties will invest in the development of the new biosimilar. Lupin will receive an initial payment of $10 million upon execution of the agreement and total development and regulatory milestone payments up to $50 million. The profits from the defined markets will be shared between the two companies.Certolizumab Pegol is a recombinant, humanized antibody Fab' fragment, with specificity for human tumor necrosis factor alpha (TNFα), conjugated to an approximately 40kDa polyethylene glycol. It is indicated for the treatment of patients with rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, psoriatic arthritis, non-radiographic axial spondyloarthritis, moderate-to-severe plaque psoriasis and Crohn’s disease.“Our global development and commercialization partnership with Zentiva, with its pan- European focus, enables Lupin to commercialize this unique biosimilar in its core markets and through Zentiva in Europe,” said Fabrice Egros, President of Corporate Development, Lupin. “This partnership underscores our dedication to improving the quality of life for individuals living with chronic conditions and ensuring accessibility and affordability of transformative therapies worldwide.

Next Story
Real Estate

Tokenisation is definitely the future of real-estate projects in India

Nisus Finance is carving a distinctive space in India’s real-estate funding ecosystem through a sharp mix of structured finance, asset management and transaction advisory. In an exclusive conversation with CW, Amit Goenka, Chairman and Founder, shares insights into the company’s unique approach to urban infrastructure finance. He discusses how Nisus Finance is not only expanding within India but also venturing into emerging markets, offering tailor-made solutions for urban development projects.How would you define your core business model and what differentiates you in this space..

Next Story
Equipment

We're building India's top platform for construction equipment rental

Janardhan Reddy grew up in a construction environment in Tumkur, Karnataka, where his father, a Class 1 PWD contractor, managed owned and rented equipment. This early exposure gave him deep insights into the sector. Today, he leads AUEQI (pronounced Aaki), short for ‘An Aura of Equipment’ – a tech-driven platform simplifying rentals and boosting productivity. Recognised as an innovator by the Karnataka government, he is supported by the Rajiv Gandhi Entrepreneurship Programme and is a final-round applicant for Elevate 2024. In this conversation with CW, he shares how AUEQI is bridging cr..

Next Story
Equipment

India is shifting from buying to leasing forklifts

- Rushabh Vora, Co-Founder and Managing Director, SILA SILA, India’s leading real-estate platform, has forayed into electric material handling equipment (MHE) rental solutions through a strategic partnership with Nilkamal, marking its expansion into the manufacturing and warehousing sectors. With over 15 years of operational expertise, a workforce of 30,000+, including 1,000+ trained equipment operators and operations spanning 125+ cities, SILA is well-positioned to transform how Indian businesses approach logistics and equipment management. Founded in 2010 by brothers Rushabh and Sahil..

Advertisement

Subscribe to Our Newsletter

Get daily newsletters around different themes from Construction world.

STAY CONNECTED

Advertisement

Advertisement

Advertisement

Talk to us?